申请人:Pfizer Inc.
公开号:US20030176445A1
公开(公告)日:2003-09-18
This invention provides a compound of the formula (I):
1
or the pharmaceutically acceptable salts thereof wherein
A is independently halo; Y is —(CH
2
)
m
—, —C(O)— or —S(O)—; R
1
and R
2
are independently C
1-4
alkyl; R
3
is C
7-9
bicycloalkyl, C
5-7
azacycloalkyl or C
7-9
azabicycloalkyl, the C
7-9
bicycloalkyl, C
5-7
azacycloalkyl or C
7-9
azabicycloalkyl being optionally substituted with one, two or three substituents are independently selected from oxo, hydroxyl, C
1-4
alkyl, C
1-4
alkyloxy, C
1-4
alkyl-carbonyl, formyl, C
1-4
alkylenedioxy, and phenyl-C
1-4
alkyl; R
4
is thiazolyl, imidazolyl or oxazolyl, the thiazolyl, imidazolyl or oxazolyl being optionally substituted with one or two substituents independently selected from C
1-4
alkyl and halo; R
5
is hydrogen or C
1-4
alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5.
These compounds are useful for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.
本发明提供了式(I)的化合物或其药学上可接受的盐,其中A是独立的卤素;Y是-(CH2)m-,-C(O)-或-S(O)-;R1和R2独立地是C1-4烷基;R3是C7-9双环烷基,C5-7杂环烷基或C7-9杂双环烷基,其中C7-9双环烷基,C5-7杂环烷基或C7-9杂双环烷基可以选用一个、两个或三个取代基,所述取代基独立地选自氧代、羟基、C1-4烷基、C1-4烷氧基、C1-4烷基羰基、甲酰基、C1-4亚烷基二氧基和苯基-C1-4烷基;R4是噻唑基、咪唑基或噁唑基,所述噻唑基、咪唑基或噁唑基可以选用一个或两个取代基,所述取代基独立地选自C1-4烷基和卤素;R5是氢或C1-4烷基;m为0、1或2;n为0、1、2、3、4或5。这些化合物可用于治疗由缓激肽介导的医疗状况,如炎症、过敏性鼻炎、疼痛等。本发明还提供了包含上述化合物的制药组合物。